• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Novartis - Articles and news items

skin

Novartis’ Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause

Industry news / 15 March 2017 / Niamh Marriott, Junior Editor

Moderate-to-severe psoriasis patients treated with Cosentyx (secukinumab) rapidly regain clear skin following relapse during a treatment pause…

Sandoz biosimilar adalimumab study shows equivalent efficacy

Industry news / 14 March 2017 / Niamh Marriott, Junior Editor

Sandoz, a Novartis division, presented data for its proposed biosimilar adalimumab, GP2017, showing that their Phase III study met its primary endpoint…

Novartis receives positive CHMP opinion for lung cancer combination

Industry news / 27 February 2017 / Niamh Marriott, Digital Editor

The EMA approved Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) to treat patients with non-small cell lung cancer…

Nanobiotix appoints Oncology industry veteran as Chief Operating Officer

Industry news / 7 February 2017 / Niamh Marriott, Digital Editor

Nanobiotix, a late clinical-stage nanomedicine company, announced the appointment of Alain Dostie, a senior executive from the pharmaceutical industry, as its Chief Operating Officer. Mr Dostie will lead Nanobiotix’s operations, including development, manufacturing, market access and sales, for their lead product NBTXR3, which could obtain a CE Mark approval in 2017. Previously, Mr Dostie was […]

The Top 21…wealthiest pharma companies

Blog, Z Homepage promo / 6 February 2017 / Niamh Marriott, Digital Editor

Find out who made it to the top of our list of richest pharma companies…

Cardiovascular risk

Novartis invests in Ionis’ therapies to reduce cardiovascular risk

Industry news / 10 January 2017 / Niamh Marriott, Digital Editor

Novartis announced a collaboration and option agreement to license two novel treatments with the potential to significantly reduce cardiovascular risk…

macular degeneration

Novartis’ macular degeneration Phase III trial did not meet endpoint

Industry news / 14 December 2016 / Niamh Louise Marriott, Digital Editor

Novartis’ two pivotal Phase III clinical studies did not meet their primary endpoints to treatment of neovascular age-related macular degeneration…

Novartis’ SMS for Life 2.0 to improve access to medicines in Nigeria

Industry news / 12 December 2016 / Niamh Louise Marriott, Digital Editor

The new and enhanced SMS for Life 2.0 program will now use smartphone and tablet computers to address key operational challenges at peripheral healthcare…

Novartis’ NSCLC study shows 16.6 month progression-free survival

Industry news / 12 December 2016 / Niamh Louise Marriott, Digital Editor

Patients with ALK+ advanced non-small cell lung cancer treated with Zykadia had a median progression-free survival of 16.6 months, compared to placebo…

Novartis’ Phase II antibody trial reduces frequency of sickle cell pain crises

Industry news / 6 December 2016 / Niamh Louise Marriott, Digital Editor

Results from the Phase II study show that SEG101 an anti-P-selectin antibody, reduced the median annual rate of sickle cell-related pain crises by 45.3%…

GSK tops list ranking big pharma’s global access to medicine

Industry news / 14 November 2016 / Niamh Louise Marriott, Digital Content Producer

Read how the 2016 Access to Medicine Index ranks the top 20 pharmaceutical companies on their efforts to improve access to medicine in low- and middle-income countries…

FDA grants priority review for Novartis’ first-line treatment of HR+/HER2- advanced breast cancer

Industry news / 7 November 2016 / Niamh Louise Marriott, Digital Content Producer

The US Food and Drug Administration (FDA) accepted Novartis’ new drug application (NDA) for filing and granted priority review for LEE011 (ribociclib)…

 

Webinar: Understanding ISO Standards: ISO 14644-2:2015 Cleanroom MonitoringWATCH NOW
+ +